Renaissance Capital logo

Boundless Bio Priced, Nasdaq: BOLD

Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors.

Industry: Health Care

Latest Trade: $10.99 0.00 (0.0%)

First Day Return: -10.9%

Return from IPO: -31.3%

Industry: Health Care

We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers. Using our proprietary Spyglass platform, we identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then design and develop small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets, with the aim to prevent cancer cells from using ecDNA to express amplified oncogenes and grow, adapt, and become resistant to existing therapies. Our lead ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is currently being studied in a first-in-human, Phase 1/2 clinical trial in patients with oncogene amplified cancers.
more less
IPO Data
IPO File Date 03/06/2024
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 6.3
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/27/2024
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 6.3
Deal Size ($mm) $100
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Goldman Sachs
Leerink Partners
more
Company Data
Headquarters San Diego, CA, United States
Founded 2018
Employees 72
Website www.boundlessbio.com

Boundless Bio (BOLD) Performance